Skip to Content
Merck
CN

MKI1MAG-94K

MILLIPLEX® Mouse Kidney Injury Panel

Configurable Mouse Kidney Injury 6-Plex Panel 1

Sign In to View Organizational & Contract Pricing.

About This Item

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

MILLIPLEX® Mouse Kidney Injury Panel, Configurable Mouse Kidney Injury 6-Plex Panel 1

species reactivity

mouse

manufacturer/tradename

Milliplex®

Quality Level

200

packaging

1 ea of

assay range

accuracy: 73-98%
sensitivity: 0.001-0.041 ng/mL
(MinDC+2SD)
standard curve range: 0.001-1 ng/mL
(VEGF)
standard curve range: 0.005-5 ng/mL
(IP-10)
standard curve range: 0.01-15 ng/mL
(KIM-1)
standard curve range: 0.02-25 ng/mL
(TIMP-1)
standard curve range: 0.05-50 ng/mL
(β-2-Microglobulin)
standard curve range: 0.05-50 ng/mL
(Renin)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Other Notes

Sensitivity: Please see kit protocol for individual assay sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 6 analytes in mouse urine, serum, or plasma samples.

Analytes Included: β-2-Microglobulin, IP-10/CXCL10, KIM-1, Renin, TIMP-1, VEGF-A Note: β-2-Microglobulin and VEGF-A are to be measured in urine samples only.

Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

Features:
  • Targets biomarkers involved in renal injury, inflammation, and vascular regulation
  • Includes 6 analytes relevant to nephrotoxicity and kidney function assessment
  • Multiplex format enables simultaneous detection from minimal sample volume Compatible with mouse urine, serum, and plasma samples
  • Designed for research in acute kidney injury, drug-induced nephrotoxicity, and renal disease models
Benefits:
  • Provides a focused profile of kidney injury biomarkers in mouse models
  • Supports investigation of renal damage mechanisms and therapeutic evaluation
  • Facilitates early detection of nephrotoxicity and disease progression
  • Enables high-throughput analysis with reduced sample and reagent use
  • Delivers reproducible, sensitive results for preclinical and translational research

General description

Kidney injury can result from various factors including drug toxicity, hypertension, and metabolic disorders. Traditional markers like BUN and creatinine are often insensitive and non-specific. This panel—β-2-Microglobulin, IP-10/CXCL10, KIM-1, Renin, TIMP-1, and VEGF-A—captures key indicators of renal damage, inflammation, and vascular response. The MILLIPLEX® Mouse Kidney Injury Panel 1 enables multiplexed quantification of these biomarkers in mouse urine, serum, or plasma, supporting research in nephrotoxicity, renal disease, and therapeutic development.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Philippine Aupy et al.
Molecular therapy. Nucleic acids, 19, 371-383 (2019-12-28)
Tricyclo-DNA (tcDNA) antisense oligonucleotides (ASOs) hold promise for therapeutic splice-switching applications and the treatment of Duchenne muscular dystrophy (DMD) in particular. We have previously reported the therapeutic potential of tcDNA-ASO in mouse models of DMD, highlighting their unique pharmaceutical properties
Gene Ryan Crislip et al.
Biomolecules, 12(2) (2022-02-26)
BMAL1 is a core mammalian circadian clock transcription factor responsible for the regulation of the expression of thousands of genes. Previously, male skeletal-muscle-specific BMAL1-inducible-knockout (iMS-BMAL1 KO) mice have been described as a model that exhibits an aging-like phenotype with an
View All Related Papers

Related Content

Overview of Luminex® Multiplex Assay Technology | MILLIPLEX® Multiplex Assays

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

Multiplex Toxicity Assays | MILLIPLEX® Assays

Multiplex toxicity assays enable researchers to simultaneously measure multiple toxicity biomarkers of various organs to gain a better understanding of toxicity. Explore how MILLIPLEX® multiplex toxicity assays are advancing research on liver injury, kidney toxicity, genotoxicity, and more.

Nephrotoxicity Analysis with Kidney Toxicity Multiplex Assays | MILLIPLEX® Assays

Novel kidney toxicity biomarkers expand options for acute nephrotoxicity detection. Multiplex assays measure multiple renal damage biomarkers in small sample volumes, minimizing time and costs. See how MILLIPLEX® multiplex kidney toxicity assays detected vancomycin-induced subacute nephrotoxicity in rat models.

Quality Control Ranges - Milliplex Mouse Kidney Injury Magnetic Bead Panel 1
See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service